Other excipients than PEG might cause serious hypersensitivity reactions in COVID‐19 vaccines

Borgsteede, Sander D.; Geersing, T H; Tempels‐Pavlica, Z.

doi:10.1111/all.14774

Cited by 34 publications

(45 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An adrenaline (epinephrine) injector should be readily available to treat any anaphylactic event. 120,133,136,138 In conclusion, current evidence shows that allergy might play a protective role in COVID-19 with the involvement of eosinophilia, There is a current need to improve our understanding of the underlying mechanisms involved in the vaccines adverse reactions and their culprit components to ensure their safety and public compliance.…”

Section: Asthmamentioning

confidence: 97%

“…Trometamol is added as a buffer in the Moderna vaccine and there has been a case report of anaphylaxis to this excipient in an intravenously administered radiocontrast agent. 133 Beta‐propiolactone (BPL), used to inactivate the virus, might induce an immune complex‐like reaction after vaccination, 121 which might cause an adverse reaction after a booster dose injection of the rabies human diploid cell vaccine. 134 , 135 Similar immunological mechanisms might be implicated in the adverse reactions associated with two widely used COVID‐19 vaccines in China, BBIBP‐CorV (Sinopharm) and Sinovac‐CoronaVac (Sinovac Life Sciences), which also contain BPL to inactivate SARS‐CoV‐2.…”

Section: Vaccination Of Covid‐19 and Allergymentioning

confidence: 99%

“…An adrenaline (epinephrine) injector should be readily available to treat any anaphylactic event. 120 , 133 , 136 , 138 …”

Section: Vaccination Of Covid‐19 and Allergymentioning

confidence: 99%

See 2 more Smart Citations

Recent advances and developments in COVID‐19 in the context of allergic diseases

Ding

Sun

Sokołowska

et al. 2021

Clinical & Translational All

View full text Add to dashboard Cite

Background Since the first reports of coronavirus disease 2019 (COVID‐19) in Wuhan, China, in December 2019, there have been 198 million confirmed cases worldwide as of August 2021. The scientific community has joined efforts to gain knowledge of the newly emerged virus named severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the immunopathological mechanisms leading to COVID‐19, and its significance for patients with allergies and asthma. Methods Based on the current literature, recent advances and developments in COVID‐19 in the context of allergic diseases were reviewed. Results and Conclusions In this review, we discuss the prevalence of COVID‐19 in subjects with asthma, attacks of hereditary angioedema, and other allergic diseases during COVID‐19. Underlying mechanisms suggest a protective role of allergy in COVID‐19, involving eosinophilia, SARS‐CoV‐2 receptors expression, interferon responses, and other immunological events, but further studies are needed to fully understand those associations. There has been significant progress in disease evaluation and management of COVID‐19, and allergy care should continue during the COVID‐19 pandemic. The European Academy of Allergy & Clinical Immunology (EAACI) launched a series of statements and position papers providing recommendations on the organization of the allergy clinic, handling of allergen immunotherapy, asthma, drug hypersensitivity, allergic rhinitis, and other allergic diseases. Treatment of allergies using biologics during the COVID‐19 pandemic has also been discussed. Allergic reactions to the COVID‐19 vaccines, including severe anaphylaxis, have been reported. Vaccination is a prophylactic strategy that can lead to a significant reduction in the mortality and morbidity associated with SARS‐CoV‐2 infection, and in this review, we discuss the proposed culprit components causing rare adverse reactions and recommendations to mitigate the risk of anaphylactic events during the administration of the vaccines.

show abstract

Section: Asthmamentioning

confidence: 97%

Section: Vaccination Of Covid‐19 and Allergymentioning

confidence: 99%

See 1 more Smart Citation

Recent advances and developments in COVID‐19 in the context of allergic diseases

Ding

Sun

Sokołowska

et al. 2021

Clinical & Translational All

View full text Add to dashboard Cite

show abstract

“…Furthermore, there are speculations that polyethylene glycol (PEG) , a constituent of COVID-19 vaccines, is a definitive allergen 32,33 . The atomic weight of PEG varies and PEG with higher molecular weight, when present in higher concentration, has been documented to promote allergic reactions [34][35][36] .…”

Section: Presentation Of Concernsmentioning

confidence: 99%

SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity?

Reuben¹,

Adogo²

2021

Rev. saúde pública

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic is significantly causing unprecedented clinical, socioeconomic, and public health challenges globally. The successful global administration of effective, safe and sustainable vaccine(s) is widely believed to be crucial in mitigating as well as preventing COVID-19. However, the rising cases of severe adverse events following immunization (AEFI) with COVID-19 vaccines including thrombosis, thrombocytopenia, and in some instances, death have created serious global concerns and could enormously contribute to vaccine hesitancy. Although the complete underlying pathophysiology and immunopathology of the COVID-19 vaccines related to AEFI, including thrombosis and/or anaphylaxis, are yet to be determined, exploring possible immuno-hypersensitivity could be crucial in the mechanisms associated with these reactions, thereby mitigating their occurrences as well as restoring confidence in vaccine administration for a COVID-19 free world.

show abstract

“…The vaccination for children 5–11 years-old is less concentrated and contains excipients such as polyethylene glycol (PEG) and trometamol, but not polysorbates. Therefore, an allergic reaction could occur for one of these excipients, although allergic reactions to trometamol are exceptionally reported [ 3 ]. Clinical data on the BNT162b2 vaccine in children aged 5 to 11 years are reported by Centers for Disease Control and Prevention [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5–11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP)

et al. 2022

View full text Add to dashboard Cite

BNT162b2 vaccine, developed by BioNTech and Pfizer ha recently approved for use in children aged 5 to 11 years. Recent data show evidence of safety on the administration and serious adverse events have been rarely reported. However, allergic systemic reactions could occur. In some cases, a correct allergic evaluation allows identifying patients at risk of developing an anaphylactic reaction. Risk assessment of allergic reactions to COVID-19 vaccines is useful to limit contraindications to vaccination and help to safely vaccinate people supposed to be at risk of allergic reactions.

show abstract

Other excipients than PEG might cause serious hypersensitivity reactions in COVID‐19 vaccines

Cited by 34 publications

References 7 publications

Recent advances and developments in COVID‐19 in the context of allergic diseases

Recent advances and developments in COVID‐19 in the context of allergic diseases

SARS-CoV-2 vaccines–induced thrombotic thrombocytopenia: should we consider immuno-hypersensitivity?

Management of BNT162b2 mRNA COVID-19 vaccine in children aged 5–11 years with allergies, asthma, and immunodeficiency: consensus of the Italian Society of Pediatric Allergy and Immunology (SIAIP)

Contact Info

Product

Resources

About